Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™

Contributed by: Business Wire

Logo

Tags

Research

Medical Supplies

FDA

Clinical Trials

Biotechnology

Health

Pharmaceutical

General Health

Science

Steel Therapeutics, Fizurex, toxicology study

More Like This

Altasciences Chosen by Steel Therapeutics to Support the Launch of Pivotal Toxicology Study for Fizurex™

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine

InterAx and Alveus Announce Strategic Research and Licensing Agreement to Develop Differentiated Therapeutic Candidate for Metabolic Disease

PR Newswire associated0

Telix to Add FAP-Targeting Candidates to Theranostic Pipeline

aXichem Announces Publication of CrossFit Study in Leading Sports Journal - Validates aXivite as a High-Intensity Performance Supplement

CORRECTING and REPLACING Altasciences Supports Metsera in Their Early-Stage Clinical Trials for Obesity